Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 275 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride Clear all

Conditions: Influenza
Interventions: VXA-A1.1, Fluzone®, Placebo Tablets, Saline Solution for Placebo IM Injection; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Costa Mesa, California

Conditions: Analgesia
Interventions: Naloxone, Saline; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Acute Pain, Wound Care, Posttraumatic Stress Disorder
Interventions: ketamine, Fentanyl; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Central Centrifugal Cicatricial Alopecia
Interventions: Platelet-Rich Plasma (PRP) Injections, Saline; Biological · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Covid19
Interventions: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase), 0.9%sodium chloride; Drug
Lead sponsor: Jon Simmons; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Herpes Zoster
Interventions: Herpes zoster vaccine GSK1437173A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more

Conditions: Glabellar Frown Lines
Interventions: Botulinum toxin, Type A, 0.9% sterile, unpreserved saline; Biological · Other
Lead sponsor: Evolus, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Influenza Type A, Influenza Type B, Influenza
Interventions: SAB-176, Normal Saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Enhanced Recovery After Surgery in a Pediatric Population
Interventions: Caffeine citrate 15mg/kg, 0.9% Sodium Citrate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 3 Years to 12 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoarthritis, Hip
Interventions: Dexamethasone, Bupivacaine, Epinephrine, Lumbar Plexus Nerve Block, Saline; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Ischemic Stroke
Interventions: Privigen, Normal Saline; Biological · Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 45 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Blood Loss, Surgical
Interventions: Trasylol (Aprotinin, BAYA0128), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 12
States / cities: Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 8 more

Conditions: Intermittent Claudication
Interventions: Trans sodium crocetinate (TSC), 0.9% normal saline; Drug
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more

Conditions: Surgery, Sedation
Interventions: Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: BPD - Bronchopulmonary Dysplasia, Apnea of Prematurity, Hemodynamic Instability, Intubation
Interventions: Caffeine Citrate, Placebo (Normal Saline); Drug
Lead sponsor: Jennifer Shepherd; Other
Eligibility: Up to 1 Day
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Von Willebrand Disease
Interventions: Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII); Biological · Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 10
States / cities: Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more

Conditions: Alcohol Withdrawal
Interventions: Ketamine, Dexmedetomidine, Normal saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Influenza
Interventions: GSK Biologicals' FluLaval®, Placebo (saline), GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Milford, Massachusetts • Salisbury, North Carolina • Winston-Salem, North Carolina

Conditions: Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions: Lenzilumab, Standard of Care; Biological · Drug
Lead sponsor: Humanigen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 18
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more

Conditions: Pain, Postoperative
Interventions: Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine; Drug · Other
Lead sponsor: Neumentum, Inc.; Other
Eligibility: 18 Years to 64 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab, Placebo; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more

Conditions: Spinal Fusion
Interventions: Dexamethasone injection, Saline injection; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 10 Years to 18 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: COVID, COVID-19, Corona Virus Infection
Interventions: Sarilumab 200 MG/1.14 ML Subcutaneous Solution, Placebo; Drug
Lead sponsor: BayCare Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: Clearwater, Florida • St. Petersburg, Florida • Tampa, Florida

Conditions: Kidney Failure
Interventions: rhC1INH, Saline Solution; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

RM1 Project 1 - tAN Naloxone

RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain

Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population

Systemic Steroids for Peripheral Nerve Blocks

IVIG in Acute Ischemic Stroke: A Pilot Study

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

Oral Versus Intravenous Sedation for Ocular Procedures

Early Caffeine in Preterm Neonates

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Spinal Fusions Steroid Study

Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function